Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

14.82
+0.37002.56%
Post-market: 14.80-0.0200-0.13%19:59 EDT
Volume:29.34M
Turnover:432.83M
Market Cap:6.71B
PE:-21.00
High:15.11
Open:14.65
Low:14.10
Close:14.45
52wk High:15.30
52wk Low:1.76
Shares:452.97M
Float Shares:394.00M
Volume Ratio:1.12
T/O Rate:7.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7058
EPS(LYR):-1.0941
ROE:-40.36%
ROA:-20.31%
PB:9.12
PE(LYR):-13.55

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise

Reuters
·
May 08

Sector Update: Health Care

MT Newswires Live
·
May 08

BUZZ-Iovance Biotherapeutics falls on Q1 revenue miss

Reuters
·
May 07

Iovance Biotherapeutics Shares Fall 12% Premarket After Wider-Than-Expected Q1 Adj. Loss

THOMSON REUTERS
·
May 07

Stock Track | Iovance Biotherapeutics Plunges 7.09% in Pre-market After Missing Q1 Earnings and Revenue Estimates

Stock Track
·
May 07

Iovance Biotherapeutics Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $71.430M Miss $78.396M Estimate

Benzinga Earnings
·
May 07

BRIEF-Iovance Biotherapeutics Q1 Revenue USD 71.43 Million

Reuters
·
May 07

Iovance Biotherapeutics Inc - Guides Q2 2026 Revenue $86 Mln-$88 Mln, FY2026 $350 Mln-$370 Mln

THOMSON REUTERS
·
May 07

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

GlobeNewswire
·
May 07

Earning Preview: Iovance Biotherapeutics, Inc. this quarter’s revenue is expected to decrease by 4.05%, and institutional views are bullish

Earnings Agent
·
May 01

Iovance Biotherapeutics to report first-quarter results, host conference call and webcast

Reuters
·
Apr 27

Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026

GlobeNewswire
·
Apr 27

Will FDA’s RP1 Setback Refocus Iovance Biotherapeutics' (IOVA) Post-Checkpoint Melanoma Narrative?

Simply Wall St.
·
Apr 22

Iovance grants 135,470 inducement stock options priced at $3.8 per share

Reuters
·
Apr 18

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 18

Iovance Biotherapeutics announces annual shareholder meeting webcast

Reuters
·
Apr 18

Iovance Biotherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Apr 11

Analysts Offer Insights on Healthcare Companies: Daré Bioscience (DARE) and Iovance Biotherapeutics (IOVA)

TIPRANKS
·
Apr 11

Replimune CRL positive for Iovance in near-term, says Chardan

TIPRANKS
·
Apr 11

Unusually active option classes on open April 10th

TIPRANKS
·
Apr 10